Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 3/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 7/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6440257 | 1.00 | TP53 (0.41) | TP53MAPTSMN1; SMN2POLBCCR2 | |
| SCHEMBL6412976 | 0.91 | MAPT (0.40) | TP53MAPTSMN1; SMN2POLBCCR2 | |
| SCHEMBL6412964 | 0.91 | MAPT (0.40) | TP53MAPTSMN1; SMN2POLBCCR2 | |
| SCHEMBL6418314 | 0.89 | MAPT (0.39) | TP53MAPTSMN1; SMN2POLBCCR2 | |
| SCHEMBL6418336 | 0.89 | MAPT (0.39) | TP53MAPTSMN1; SMN2POLBCCR2 | |
| SCHEMBL6415683 | 0.89 | CSNK2A1 (0.45) | TP53MAPTSMN1; SMN2POLBCCR2 | |
| SCHEMBL6415701 | 0.89 | CSNK2A1 (0.45) | TP53MAPTSMN1; SMN2POLBCCR2 | |
| SCHEMBL6431148 | 0.88 | TP53 (0.41) | TP53MAPTSMN1; SMN2POLBCCR2 | |
| SCHEMBL6431156 | 0.88 | TP53 (0.41) | TP53MAPTSMN1; SMN2POLBCCR2 | |
| SCHEMBL6502277 | 0.87 | SMN1; SMN2 (0.47) | TP53MAPTSMN1; SMN2POLBCCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143382-A1 | Heterocyclic compounds as pharmaceutically active compounds | 4SC AG (DE) | 2005-06-30 | — | — | US | disclosed |
| WO-2005044270-A1 | OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS | 4SC AG (DE) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143382-A1 | Heterocyclic compounds as pharmaceutically active compounds | NR5A2, NR1H2, NR2C2 | TP53 4485/4885MAPT 4420/4885SMN1; SMN2 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.